MENTEN

Backed by top-tier VCs including Uncork Capital, Khosla Ventures, Social Impact Capital, and Y-Combinator, Menten AI is enabling a new type of drug for currently undruggable targets using machine learning. The Menten AI platform designs peptide macrocycles in a larger chemical space (10 50 compared to 10 9 for high throughput platforms) and in record time (8 weeks vs 1-2 year in industry). This equates to 10,000x greater sampling power in ⅙ the time with >50% in vitro hit success compared to 9% in industry. We have validated the platform by creating multiple hit molecules across a variety of drug targets including an anti-viral peptide forCovid-19... Building the world's most advanced generative AI platform for peptide therapeutics.

Also known as: Menten AI